MedTrace Logo

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

NCT00189293 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2022-02-07

No results posted yet for this study

Summary

The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative therapy (laser or electrocautery therapy) with that from just ablative therapy treatment alone.

Conditions

  • Genital Warts

Interventions

DRUG

Imiquimod

Imiquimod 5% cream three times per week for 4 weeks (1 sachet) 1 or 2 sachet(s)

OTHER

vehicle cream

vehicle cream three times per week for 4 weeks (1 sachet) 1 or 2 sachet(s)

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Fausto Boselli, MD · Unità di Ginecologia Preventiva e Oncologica Università di Modena e Reggio Emilia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189293 on ClinicalTrials.gov